Table 3.
Clinical outcomes of patients undergoing single versus multiple Gamma Knife treatments.
| Author (year) | Clinical evaluation method | GKRS max dose (Gy) | Study endpoints | Results |
|---|---|---|---|---|
| BNI scores of I–IIIb at 1-y for idiopathic TN | 75% | |||
| BNI scores of I–IIIb at 3-y for idiopathic TN | 60% | |||
| BNI scores of I–IIIb at 5-y for idiopathic TN | 58% | |||
| Verheul et al. [33] (2010) | BNI | 1st treatment: 80 2nd treatment: 80 |
BNI scores of I–IIIb at 1-y for MS-related TN | 56% |
| BNI scores of I–IIIb at 3-y for MS-related TN | 30% | |||
| BNI scores of I–IIIb at 5-y for MS-related TN | 20% | |||
| 5-y idiopathic retreatment pain relief rate | 75% | |||
| 5-y MS retreatment pain relief rate | 46% | |||
|
| ||||
| Pain outcome in primary versus secondary GKRS | P = NS | |||
| Park et al. [34] (2011) | BNI | 1st treatment mean: 82.4 ± 6.25 2nd treatment mean: 81 ± 4.89 |
Primary GKRS facial numbness | 21% |
| Secondary GKRS facial numbness | 45.8% | |||
|
| ||||
| BNI score of I–III at 1-y | 75% | |||
| Patients requiring additional surgery | 41% | |||
| Little et al. [35] (2009) | BNI | 1st treatment: 80 2nd treatment: 40–50 |
Patients with mild facial numbness | 76% |
| Patients with bothersome facial numbness | 8% | |||
| Patients with eye symptoms | 12% | |||
|
| ||||
| BNI scores of I–IIIb at 1-y | 82.6% | |||
| Zorro et al. [3] (2009) | BNI | Median: 80 | BNI scores of I–IIIb at 3-y | 73.9% |
| BNI scores of I–IIIb at 5-y | 54% | |||
| Patients with facial sensory dysfunction | 5.4% | |||
|
| ||||
| 1-y no previous treatment excellent outcome rate | 82.5% | |||
| 1-y previous treatment excellent outcome rate | 69.4% | |||
| Fountas et al. [36] (2007) | EGFP | Median: 80 | 2-y no previous treatment excellent outcome rate | 78% |
| 2-y previous treatment excellent outcome rate | 63.5% | |||
| No previous treatment paresthesia rate | 15.8% | |||
| Previous treatment paresthesia rate | 16.3% | |||
|
| ||||
| 1-y no previous treatment excellent outcome rate | 80.8% | |||
| 1-y previous treatment excellent outcome rate | 69.2% | |||
| Fountas et al. [37] (2006) | EGFP | Median: 80 | 2-y no previous treatment excellent outcome rate | 64% |
| 2-y previous treatment excellent outcome rate | 11.5% | |||
| No previous treatment facial numbness rate | 17.3% | |||
| Previous treatment facial numbness rate | 16% | |||
|
| ||||
| 1st treatment excellent outcome rate | 56% | |||
| 1st treatment good outcome rate | 13.5% | |||
| Huang et al. [38] (2008) | EGFP | 1st treatment mean: 79 2nd treatment mean: 52 |
1st treatment fair outcome rate | 7.9% |
| 2nd treatment excellent outcome rate | 55% | |||
| 2nd treatment good outcome rate | 5% | |||
| Facial numbness associated with repeat GKRS | P = 0.007 | |||
|
| ||||
| Huang et al. [39] (2008) | EGFP | Mean: 60.7 | Excellent outcome rate after GKRS to the tumor | 57% |
| Excellent outcome rate after GKRS to CN V | 50% | |||
BNI: Barrow Neurological Institute; CN: cranial nerve; EGFP: excellent-good-fair-poor; GKRS: Gamma Knife radiosurgery; NS: nonsignificant.